Us was Indivior Pharmaceuticals’s largest segment in fiscal 2025, bringing in $794.00M of $980.00M (81%).
| Segment | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Us | $732.00M | $912.00M | $704.00M | $794.00M |
| Rest Of World | — | $181.00M | $179.00M | $186.00M |
| Most Of World | $169.00M | — | — | — |
| Total | $901.00M | $1.09B | $883.00M | $980.00M |
Indivior Pharmaceuticals brought in $980.00M from its two segments in fiscal 2025, the year ended December 31, 2025. That was up 11.0% from $883.00M in fiscal 2024. Us was the largest at $794.00M (81.0%), ahead of Rest Of World at $186.00M (19.0%).
Compared with fiscal 2024, Us grew 12.8% to $794.00M and Rest Of World grew 3.9% to $186.00M.
Indivior Pharmaceuticals began breaking out Rest Of World in fiscal 2023, when it brought in $181.00M. Indivior Pharmaceuticals stopped reporting Most Of World as a separate segment after fiscal 2022, when it brought in $169.00M.
United States was Indivior Pharmaceuticals’s largest region in fiscal 2023, bringing in $912.00M of $1.09B (83%).
| Geography | FY 2021 | FY 2022 | FY 2023 |
|---|---|---|---|
| United States | $603.00M | $731.00M | $912.00M |
| Rest Of World | $181.00M | $164.00M | $176.00M |
| United Kingdom | $7.00M | $6.00M | $5.00M |
| Total | $791.00M | $901.00M | $1.09B |
Indivior Pharmaceuticals brought in $1.09B from its three regions in fiscal 2023, the year ended December 31, 2023. That was up 21.3% from $901.00M in fiscal 2022. United States was the largest at $912.00M (83.4%), ahead of Rest Of World at $176.00M (16.1%) and United Kingdom at $5.00M (0.5%).
Compared with fiscal 2022, United States grew 24.8% to $912.00M and Rest Of World grew 7.3% to $176.00M. From fiscal 2021 to 2023, combined revenue from these regions grew from $791.00M to $1.09B, a compound annual growth rate of 17.5%. United States' share of the total rose from 76.2% to 83.4%.
Sublocade was Indivior Pharmaceuticals’s largest revenue line in fiscal 2023, bringing in $630.00M of $1.09B (58%).
| Products and services [axis] | FY 2021 | FY 2022 | FY 2023 |
|---|---|---|---|
| Sublingual/Other | $530.00M | $465.00M | $421.00M |
| Sublocade | $244.00M | $408.00M | $630.00M |
| Perseris | $17.00M | $28.00M | $42.00M |
| Total | $791.00M | $901.00M | $1.09B |
Indivior Pharmaceuticals brought in $1.09B from its three revenue lines in fiscal 2023, the year ended December 31, 2023. That was up 21.3% from $901.00M in fiscal 2022. Sublocade was the largest at $630.00M (57.6%), ahead of Sublingual/Other at $421.00M (38.5%) and Perseris at $42.00M (3.8%).
Compared with fiscal 2022, Sublocade grew fastest, up 54.4% to $630.00M, while Sublingual/Other fell the most, down 9.5% to $421.00M. From fiscal 2021 to 2023, combined revenue from these revenue lines grew from $791.00M to $1.09B, a compound annual growth rate of 17.5%. Sublocade's share of the total rose from 30.8% to 57.6%.
Indivior Pharmaceuticals (INDV) reports its revenue by segment, by geography and by products and services [axis]. In fiscal 2025, Us was its largest segment, bringing in $794.00M (81.0% of the total), followed by Rest Of World at $186.00M (19.0%).
Us was Indivior Pharmaceuticals' largest segment in fiscal 2025, bringing in $794.00M, or 81.0% of the $980.00M total across its two segments.
United States was Indivior Pharmaceuticals' largest region in fiscal 2023, bringing in $912.00M, or 83.4% of the $1.09B total across its three regions.
Sublocade was Indivior Pharmaceuticals' largest revenue line in fiscal 2023, bringing in $630.00M, or 57.6% of the $1.09B total across its three revenue lines.
Us grew faster than Rest Of World in fiscal 2025, up 12.8% from $704.00M to $794.00M. Rest Of World grew 3.9% to $186.00M.
Every figure comes from Indivior Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Indivior Pharmaceuticals gives it, and years follow its fiscal calendar.
Indivior Pharmaceuticals' revenue by segment goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.